Published in J Autoimmun on December 01, 1999
Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest (2001) 3.01
Chronic intestinal pseudo-obstruction. World J Gastroenterol (2008) 2.29
Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction. Gut (2004) 2.04
HuR function in disease. Front Biosci (Landmark Ed) (2012) 1.86
Chronic intestinal pseudo-obstruction: systematic histopathological approach can clinch vital clues. Virchows Arch (2014) 1.39
Novel DNA-binding properties of the RNA-binding protein TIAR. Nucleic Acids Res (2005) 1.20
Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. Mol Cancer (2011) 1.10
Association between the neuron-specific RNA-binding protein ELAVL4 and Parkinson disease. Hum Genet (2005) 1.09
RNA-binding analyses of HuC and HuD with the VEGF and c-myc 3'-untranslated regions using a novel ELISA-based assay. Nucleic Acids Res (2000) 1.04
Anti-enteric neuronal antibodies and the irritable bowel syndrome. J Neurogastroenterol Motil (2012) 0.98
Neuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures. J Neuroinflammation (2014) 0.90
Acute on chronic intestinal pseudo-obstruction as a cause of death in a previously healthy twenty-year-old male. Dig Dis Sci (2006) 0.87
Serotonin transporter variant drives preventable gastrointestinal abnormalities in development and function. J Clin Invest (2016) 0.85
Mutant copper-zinc superoxide dismutase associated with amyotrophic lateral sclerosis binds to adenine/uridine-rich stability elements in the vascular endothelial growth factor 3'-untranslated region. J Neurochem (2009) 0.84
Neurogenic chronic intestinal pseudo-obstruction: antineuronal antibody-mediated activation of autophagy via Fas. Gastroenterology (2008) 0.78
Distribution of TMEM100 in the mouse and human gastrointestinal tract--a novel marker of enteric nerves. Neuroscience (2013) 0.77
Anti-Hu antibodies activate enteric and sensory neurons. Sci Rep (2016) 0.75
Enteric Nervous System: Neuropathic Gastrointestinal Motility. Dig Dis Sci (2016) 0.75
Migration pathways of sacral neural crest during development of lower urogenital tract innervation. Dev Biol (2017) 0.75
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology (1976) 4.93
Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology (2004) 4.74
Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology (2008) 4.31
Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology (2007) 3.83
Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology (2012) 3.79
Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med (2000) 3.57
CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol (2001) 3.44
Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology (2009) 3.43
Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology (2011) 3.30
NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology (2008) 3.21
Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med (1994) 3.16
Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest (2001) 3.01
Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects. Ann N Y Acad Sci (1976) 2.48
Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs. J Exp Med (1975) 2.43
Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology (2007) 2.32
Immunoglobulins promote remyelination in the central nervous system. Ann Neurol (1990) 2.27
Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med (1999) 2.12
CNS aquaporin-4 autoimmunity in children. Neurology (2008) 2.10
Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology (1998) 2.08
A comparison of carotid angioplasty with stenting versus endarterectomy with regional anesthesia. J Vasc Surg (1998) 2.05
Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. Neurology (1977) 1.78
The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J (2004) 1.74
A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology (2007) 1.70
Cancer susceptibility variants and the risk of adult glioma in a US case-control study. J Neurooncol (2011) 1.69
Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology (2011) 1.64
Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol (2001) 1.55
Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies. J Exp Med (1976) 1.53
Myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability. Neurology (1999) 1.52
Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med (1978) 1.51
Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology (1998) 1.46
ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol (2001) 1.45
Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann N Y Acad Sci (1976) 1.43
Seronegativity for type 1 antineuronal nuclear antibodies ('anti-Hu') in subacute sensory neuronopathy patients without cancer. Neurology (1993) 1.41
Immunologic properties of the main encephalitogenic peptide from the basic protein of human myelin. J Immunol (1970) 1.39
Neurological autoimmunity targeting aquaporin-4. Neuroscience (2009) 1.39
New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol (2000) 1.38
Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature (1980) 1.38
Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol (2001) 1.36
The case for a descriptive generic nomenclature: clarification of immunostaining criteria for PCA-1, ANNA-1, and ANNA-2 autoantibodies. Neurology (1994) 1.36
Transitory expression of Thy-1 antigen in skeletal muscle development. Nature (1977) 1.32
Thy-1: a differentiation marker of potential mammary myoepithelial cells in vitro. Proc Natl Acad Sci U S A (1978) 1.31
The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Ann N Y Acad Sci (1976) 1.30
Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve (1982) 1.28
Immunopharmacological disease: a break in tolerance to receptor sites. Lancet (1971) 1.23
Dystonia and cerebellar atrophy in Cacna1a null mice lacking P/Q calcium channel activity. FASEB J (2001) 1.21
End-plate potentials in experimental autoimmune myasthenia gravis in rats. Ann N Y Acad Sci (1976) 1.21
Paraneoplastic cerebellar degeneration: a clinical comparison of patients with and without Purkinje cell cytoplasmic antibodies. Mayo Clin Proc (1990) 1.19
High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI. Magn Reson Med (2009) 1.19
Beta subunit heterogeneity in N-type Ca2+ channels. J Biol Chem (1996) 1.19
Brain-derived fibroblast growth factor: identity with a fragment of the basic protein of myelin. Proc Natl Acad Sci U S A (1978) 1.18
Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin. J Exp Med (1986) 1.17
Identification of three subunits of the high affinity omega-conotoxin MVIIC-sensitive Ca2+ channel. J Biol Chem (1996) 1.09
Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. Mayo Clin Proc (1998) 1.09
Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma. Mayo Clin Proc (1992) 1.09
Myasthenia gravis with autoimmune autonomic neuropathy. Auton Neurosci (2001) 1.08
Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology (2014) 1.08
Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J Neuropathol Exp Neurol (1978) 1.08
Absence of cortical demyelination in neuromyelitis optica. Neurology (2010) 1.07
Autoimmune paraneoplastic cerebellar degeneration: ultrastructural localization of antibody-binding sites in Purkinje cells. Neurology (1988) 1.07
Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci (1987) 1.06
Experimental autoimmune myasthenia: clinical, neurophysiologic, and pharmacologic aspects. Ann N Y Acad Sci (1976) 1.05
Region of peptide 125-147 of acetylcholine receptor alpha subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies. Proc Natl Acad Sci U S A (1985) 1.04
Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol (1996) 1.03
Reduced muscle acetylcholine sensitivity in rats immunised with acetylcholine receptor. Nature (1976) 1.02
Autoantibodies in paraneoplastic cerebellar degeneration bind to cytoplasmic antigens of Purkinje cells in humans, rats and mice and are of multiple immunoglobulin classes. J Neuroimmunol (1988) 1.02
Genetic control of experimental autoimmune myasthenia gravis in mice. I. Lymphocyte proliferative response to acetylcholine receptors is under H-2-linked Ir gene control. J Immunol (1979) 1.02
Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J Neuropathol Exp Neurol (1987) 1.01
Monoclonal autoantibodies to acetylcholine receptors: evidence for a dominant idiotype and requirement of complement for pathogenicity. Ann N Y Acad Sci (1981) 1.01
Nutritional status of urban homebound older adults. Am J Clin Nutr (1997) 0.99
Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow. Mayo Clin Proc (1988) 0.99
Experimental autoimmune myasthenia gravis: a sequential and quantitative study of the neuromuscular junction ultrastructure and electrophysiologic correlations. J Neuropathol Exp Neurol (1976) 0.99
Distress and quality of life in primary high-grade brain tumor patients. Support Care Cancer (2009) 0.99
Antagonism of voltage-gated calcium channels in small cell carcinomas of patients with and without Lambert-Eaton myasthenic syndrome by autoantibodies omega-conotoxin and adenosine. Cancer Res (1988) 0.98
Paraneoplastic anti-Purkinje and type I anti-neuronal nuclear autoantibodies bind selectively to central, peripheral, and autonomic nervous system cells. Lab Invest (1991) 0.98
Quantitative immunocytochemistry using an image analyzer. I. Hardware evaluation, image processing, and data analysis. J Neurosci Methods (1988) 0.98
Synthesis of an antigenic site of native acetylcholine receptor peptide 159-169 of Torpedo acetylcholine receptor alpha-chain. Biochem J (1985) 0.98
The immunopathology of myasthenia gravis. Hum Pathol (1978) 0.98
Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology (1998) 0.97
Detection of antibodies to the basic protein of human myelin by radioimmunoassay and immunofluorescence. J Immunol (1971) 0.97
What liver transplant outcomes can be expected in the uninsured who become insured via the Affordable Care Act? Am J Transplant (2013) 0.96
Antigen, host and adjuvant requirements for induction of hyperacute experimental autoimmune encephalomyelitis. Eur J Immunol (1976) 0.96
Properties of nicotinic acetylcholine receptors isolated by affinity chromatography on monoclonal antibodies. J Biol Chem (1980) 0.96
Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica. Neurology (2011) 0.95
Appearance of neurons in the developing chick gut. Dev Dyn (1995) 0.95
Acetylcholine receptors in small cell carcinomas. J Neurochem (1985) 0.95
Gynecologic cancer in patients with subacute cerebellar degeneration predicted by anti-Purkinje cell antibodies and limited in metastatic volume. Mayo Clin Proc (1990) 0.94
Immunology of the acetylcholine receptor. Immunol Commun (1976) 0.94
Amyotrophic lateral sclerosis-linked mutant SOD1 sequesters Hu antigen R (HuR) and TIA-1-related protein (TIAR): implications for impaired post-transcriptional regulation of vascular endothelial growth factor. J Biol Chem (2009) 0.94
Role of T lymphocytes in the pathogenesis of experimental autoimmune encephalomyelitis. Eur J Immunol (1973) 0.93
Neurectoderm markers retained in phenotypical skeletal muscle cells arising from a glial cell line. Nature (1979) 0.92
Lymphocytes binding basic protein of myelin; cytophilic serum antibody and effect of adjuvant. Immunology (1973) 0.92
Identification and cloning of putative human neuronal voltage-gated calcium channel gamma-2 and gamma-3 subunits: neurologic implications. Mayo Clin Proc (1999) 0.92
End-plate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis. Ann Neurol (1998) 0.92
Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology (1996) 0.91
Immunotherapy trial as diagnostic test in evaluating patients with presumed autoimmune gastrointestinal dysmotility. Neurogastroenterol Motil (2014) 0.91
Selected IgG rapidly induces Lambert-Eaton myasthenic syndrome in mice: complement independence and EMG abnormalities. Muscle Nerve (1988) 0.91
Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. 1975. Neurology (1998) 0.91